GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » EV-to-FCF

Fusion Antibodies (LSE:FAB) EV-to-FCF : -1.51 (As of May. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Fusion Antibodies's Enterprise Value is £3.18 Mil. Fusion Antibodies's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 was £-2.11 Mil. Therefore, Fusion Antibodies's EV-to-FCF for today is -1.51.

The historical rank and industry rank for Fusion Antibodies's EV-to-FCF or its related term are showing as below:

LSE:FAB' s EV-to-FCF Range Over the Past 10 Years
Min: -368.25   Med: -17.13   Max: -0.38
Current: -1.33

During the past 9 years, the highest EV-to-FCF of Fusion Antibodies was -0.38. The lowest was -368.25. And the median was -17.13.

LSE:FAB's EV-to-FCF is ranked worse than
100% of 372 companies
in the Biotechnology industry
Industry Median: 8.36 vs LSE:FAB: -1.33

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), Fusion Antibodies's stock price is £0.038. Fusion Antibodies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was £-0.086. Therefore, Fusion Antibodies's PE Ratio for today is At Loss.


Fusion Antibodies EV-to-FCF Historical Data

The historical data trend for Fusion Antibodies's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies EV-to-FCF Chart

Fusion Antibodies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only -1.80 -73.72 -25.15 -23.18 -5.30

Fusion Antibodies Semi-Annual Data
Mar15 Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -23.18 - -5.30 -

Competitive Comparison of Fusion Antibodies's EV-to-FCF

For the Biotechnology subindustry, Fusion Antibodies's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fusion Antibodies's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Antibodies's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Fusion Antibodies's EV-to-FCF falls into.



Fusion Antibodies EV-to-FCF Calculation

Fusion Antibodies's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=3.184/-2.107
=-1.51

Fusion Antibodies's current Enterprise Value is £3.18 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fusion Antibodies's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 was £-2.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fusion Antibodies  (LSE:FAB) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Fusion Antibodies's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.038/-0.086
=At Loss

Fusion Antibodies's share price for today is £0.038.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fusion Antibodies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was £-0.086.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Fusion Antibodies EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Fusion Antibodies (LSE:FAB) Business Description

Traded in Other Exchanges
N/A
Address
1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL
Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies (LSE:FAB) Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor 10-21-2022